跳转至内容
Merck
CN

69782

L-(+)-乳酸 溶液

purum, ~20% (L-lactic acid in water)

别名:

(S)-2-羟基丙酸, 肌乳酸

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C3H6O3
化学文摘社编号:
分子量:
90.08
PubChem Substance ID:
UNSPSC Code:
12161700
Beilstein/REAXYS Number:
1720251
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

purum

form

liquid

concentration

~20% (L-lactic acid in water)

impurities

≤1% D-lactic acid

SMILES string

C[C@H](O)C(O)=O

InChI

1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1

InChI key

JVTAAEKCZFNVCJ-REOHCLBHSA-N

Other Notes

l(+)-乳酸盐水溶液


Still not finding the right product?

Explore all of our products under L-(+)-乳酸 溶液


pictograms

Corrosion

signalword

Danger

hcodes

Hazard Classifications

Eye Dam. 1 - Skin Corr. 1C

supp_hazards

存储类别

8A - Combustible corrosive hazardous materials

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

ppe

Eyeshields, Gloves, type ABEK (EN14387) respirator filter

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



T Isotalo et al.
BJU international, 88(1), 30-34 (2001-07-12)
To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent. Fifty-five patients in acute urinary retention were treated as
Franco Valenza et al.
Critical care (London, England), 9(6), 588-593 (2005-12-17)
Lactate measurement in the critically ill has been traditionally used to stratify patients with poor outcome. However, plasma lactate levels are the result of a finely tuned interplay of factors that affect the balance between its production and its clearance.
S Walenta et al.
Current medicinal chemistry, 11(16), 2195-2204 (2004-07-29)
A number of studies have demonstrated that malignant transformation is associated with an increase in glycolytic flux and in anaerobic and aerobic cellular lactate excretion. Using quantitative bioluminescence imaging in various primary carcinomas in patients (uterine cervix, head and neck